Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

NCT04530630 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections
Renal Transplant Rejection

Interventions

DRUG: BIC/F/TAF 50Mg-200Mg-25Mg Tablet

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]